	US 12,404,327 B2
	LILRB3-binding molecules and uses therefor
Richard Brokx, Toronto (CA); Jacqueline M. Mason, Toronto (CA); and Mark R. Bray, Oakville (CA)
Assigned to UNIVERSITY HEALTH NETWORK, Toronto (CA)
Appl. No. 17/421,705
Filed by UNIVERSITY HEALTH NETWORK, Toronto (CA)
PCT Filed Jan. 16, 2020, PCT No. PCT/CA2020/050042 § 371(c)(1), (2) Date Jul. 8, 2021, PCT Pub. No. WO2020/146946, PCT Pub. Date Jul. 23, 2020.
Claims priority of provisional application 62/794,064, filed on Jan. 18, 2019.
Prior Publication US 2022/0089723 A1, Mar. 24, 2022
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/2803 (2013.01)

20 Claims

1. An antibody that binds to human LILRB3, the antibody comprising a heavy chain variable region comprising a vhCDR1, a vhCDR2, and a vhCDR3 and a light chain variable region comprising a vlCDR1, a vlCDR2, and a vlCDR3, wherein the vhCDR1, vhCDR2, vhCDR3, vlCDR1, vlCDR2 and vlCDR3 are selected from the following:

a) a vhCDR1 comprising SEQ ID NO:51, a vhCDR2 comprising SEQ ID NO:52, a vhCDR3 comprising SEQ ID NO:53, a vlCDR1 comprising SEQ ID NO:54, a vlCDR2 comprising STS, and a vlCDR3 comprising SEQ ID NO:56;

b) a vhCDR1 comprising SEQ ID NO:33, a vhCDR2 comprising SEQ ID NO:34, a vhCDR3 comprising SEQ ID NO:35, a vlCDR1 comprising SEQ ID NO:36, a vlCDR2 comprising STS, and a vlCDR3 comprising SEQ ID NO:38;

c) a vhCDR1 comprising SEQ ID NO:39, a vhCDR2 comprising SEQ ID NO:40, a vhCDR3 comprising SEQ ID NO:41, a vlCDR1 comprising SEQ ID NO:42, a vlCDR2 comprising NAK, and a vlCDR3 comprising SEQ ID NO:44;

d) a vhCDR1 comprising SEQ ID NO:45, a vhCDR2 comprising SEQ ID NO:46, a vhCDR3 comprising SEQ ID NO:47, a vlCDR1 comprising SEQ ID NO:48, a vlCDR2 comprising WAS, and a vlCDR3 comprising SEQ ID NO:50;

e) a vhCDR1 comprising SEQ ID NO:27, a vhCDR2 comprising SEQ ID NO:28, avhCDR3 comprising SEQ ID NO:29, a vlCDR1 comprising SEQ ID NO:30, a vlCDR2 comprising STS, and a vlCDR3 comprising SEQ ID NO:32;

f) a vhCDR1 comprising SEQ ID NO:57, a vhCDR2 comprising SEQ ID NO:58, a vhCDR3 comprising SEQ ID NO:59, a vlCDR1 comprising SEQ ID NO:60, a vlCDR2 comprising STS, and a vlCDR3 comprising SEQ ID NO:62;

g) a vhCDR1 comprising SEQ ID NO:63, a vhCDR2 comprising SEQ ID NO:64, a vhCDR3 comprising SEQ ID NO:65, a vlCDR1 comprising SEQ ID NO:66, a vlCDR2 comprising STS, and a vlCDR3 comprising SEQ ID NO:68;

h) a vhCDR1 comprising SEQ ID NO:69, a vhCDR2 comprising SEQ ID NO:70, a vhCDR3 comprising SEQ ID NO:71, a vlCDR1 comprising SEQ ID NO:72, a vlCDR2 comprising STS, and a vlCDR3 comprising SEQ ID NO:74;

i) a vhCDR1 comprising SEQ ID NO:75, a vhCDR2 comprising SEQ ID NO:76, a vhCDR3 comprising SEQ ID NO:77, a vlCDR1 comprising SEQ ID NO:78, a vlCDR2 comprising TTS, and a vlCDR3 comprising SEQ ID NO:80;

j) a vhCDR1 comprising SEQ ID NO:81, a vhCDR2 comprising SEQ ID NO:82, a vhCDR3 comprising SEQ ID NO:83, a vlCDR1 comprising SEQ ID NO:84, a vlCDR2 comprising STS, and a vlCDR3 comprising SEQ ID NO:86;

k) a vhCDR1 comprising SEQ ID NO:87, a vhCDR2 comprising SEQ ID NO:88, a vhCDR3 comprising SEQ ID NO:89, a vICDR1 comprising SEQ ID NO:90, a vlCDR2 comprising STS, and a vlCDR3 comprising SEQ ID NO:92;

l) a vhCDR1 comprising SEQ ID NO:93, a vhCDR2 comprising SEQ ID NO:94, a vhCDR3 comprising SEQ ID NO:95, a vlCDR1 comprising SEQ ID NO:96, a vlCDR2 comprising STS, and a vlCDR3 comprising SEQ ID NO:98; or

m) a vhCDR1 comprising SEQ ID NO:99, a vhCDR2 comprising SEQ TD NO: 100, a vhCDR3 comprising SEQ ID NO:101, a vlCDR1 comprising SEQ ID NO:102, a vlCDR2 comprising STS, and a vlCDR3 comprising SEQ ID NO:104.